Legal & General Group Plc Buys 15,009 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Legal & General Group Plc boosted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 1.7% in the 3rd quarter, HoldingsChannel reports. The fund owned 887,780 shares of the biopharmaceutical company’s stock after buying an additional 15,009 shares during the quarter. Legal & General Group Plc’s holdings in Alnylam Pharmaceuticals were worth $404,828,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Brighton Jones LLC bought a new position in shares of Alnylam Pharmaceuticals in the fourth quarter worth approximately $243,000. Geneos Wealth Management Inc. raised its holdings in Alnylam Pharmaceuticals by 372.3% during the 1st quarter. Geneos Wealth Management Inc. now owns 222 shares of the biopharmaceutical company’s stock valued at $60,000 after buying an additional 175 shares during the last quarter. First Horizon Advisors Inc. boosted its position in Alnylam Pharmaceuticals by 50.8% during the 2nd quarter. First Horizon Advisors Inc. now owns 187 shares of the biopharmaceutical company’s stock valued at $61,000 after buying an additional 63 shares during the period. Atlantic Union Bankshares Corp bought a new stake in Alnylam Pharmaceuticals in the 2nd quarter worth $30,000. Finally, Vestmark Advisory Solutions Inc. bought a new stake in Alnylam Pharmaceuticals in the 2nd quarter worth $567,000. 92.97% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Trading Down 0.4%

NASDAQ ALNY opened at $322.38 on Wednesday. The stock’s 50 day moving average is $349.24 and its 200 day moving average is $412.24. The firm has a market capitalization of $42.75 billion, a PE ratio of 188.53 and a beta of 0.36. The company has a quick ratio of 2.71, a current ratio of 2.76 and a debt-to-equity ratio of 1.28. Alnylam Pharmaceuticals, Inc. has a twelve month low of $205.87 and a twelve month high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.18). The company had revenue of $1.10 billion for the quarter, compared to the consensus estimate of $1.16 billion. Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The firm’s quarterly revenue was up 84.9% on a year-over-year basis. During the same period last year, the business earned ($0.65) EPS. Research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Yvonne Greenstreet sold 6,799 shares of the firm’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $327.65, for a total value of $2,227,692.35. Following the transaction, the chief executive officer directly owned 98,628 shares in the company, valued at $32,315,464.20. This trade represents a 6.45% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Tolga Tanguler sold 1,598 shares of the firm’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $327.65, for a total value of $523,584.70. Following the completion of the transaction, the executive vice president directly owned 36,606 shares in the company, valued at $11,993,955.90. The trade was a 4.18% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 53,923 shares of company stock worth $18,072,087 in the last 90 days. Insiders own 1.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on ALNY. Freedom Capital raised shares of Alnylam Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, February 17th. HC Wainwright reissued a “buy” rating and issued a $510.00 target price on shares of Alnylam Pharmaceuticals in a research note on Wednesday, February 18th. Morgan Stanley reduced their price target on Alnylam Pharmaceuticals from $495.00 to $408.00 and set an “equal weight” rating on the stock in a report on Friday, January 30th. Raymond James Financial reiterated an “outperform” rating and issued a $472.00 price objective on shares of Alnylam Pharmaceuticals in a report on Monday, January 12th. Finally, Weiss Ratings upgraded Alnylam Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Thursday, January 15th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $477.96.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.